Non-Employee Directors

Richard T. McKernan
Emery G. Olcott
John J. Altorelli
Phillip R. Chapman
Stephen M. McLean
Richard Upton

Richard T. McKernan, Chairman of the Board

Richard was Chairman of the Board of Agencourt BioScience Corporation and Agencourt Personal Genomics. Prior to his role as Chairman, Richard served as President of Packard Instrument Company and Board member of Packard BioScience Corporation and Canberra Industries. Richard has had 40 years of management experience with twenty years in the Life Sciences Industry. Richard's management experience includes engineering, operations, domestic and international sales and service, marketing and strategic planning. Richard has managed the turnarounds of five companies and led the acquisition and divestiture of over a dozen product lines, technologies and companies. In the life science field he has experience in nuclear, luminescent, and fluorescent counting and imaging equipment, micro plate robotic systems, immunoassay equipment and reagents. He was the lead presenter in a public bond offering and the initial public offering of Packard Bioscience Company stock and participated in the negotiations for the acquisition of Packard by PerkinElmer Corporation. During his career Mr. McKernan was a key participant on management teams that generated over $1.0 billion in shareholder wealth. Mr. McKernan was a long time member and past Board member of ALSSA, a prominent Life Sciences industry association.

Emery G. Olcott, Board Member

Emery Olcott graduated from Yale University with a degree in Industrial Management and he received an MBA from MIT's Sloan School of Management. Based on the acquisition of Sturrup Nuclear, a small failing electronics company, Emery founded Canberra Industries as an incubator for high tech start ups. The company evolved into a highly successful nuclear instrument company and a thriving Canberra Clinical Laboratory. The laboratory became the largest in New England and was sold to Corning. Canberra Industries served as a platform company for acquisitions including Radiation Management Company, Radiomatic Instrument Company, Nuclear Data, Tennelec as well as numerous European distributors. Canberra branched into the life science market with the acquisition of Packard Instrument Company from United Technologies. Packard had been failing to meet UTCs financial goals and was being discarded. Richard McKernan, a Canberra officer at the time, took control of Packard and refocused the organization and returned the company to healthy growth and profitability. Packard's product lines were expanded with internal development and acquitions of Carl Creative Systems, Biosignal and others. Packard entered into a strategic marketing agreement with Agencourt Biosciences and Emery served as a member of the Board of Directors and was an early investor. Packard and Canberra were merged into Packard Bioscience and taken public in 2001. Canberra was sold to Cogema, a French nuclear conglomerate, and Packard was purchased by PerkinElmer. Over the years, Mr Olcott's activities returned close to $1 billion to shareholder's and employees.

John J. Altorelli, Board Member

Mr. Altorelli is a Partner Dewey & LeBoeuf LLP. Mr. Altorelli's practice focuses on mergers and acquisitions, private equity, structured finance, and corporate finance transactions. Mr. Altorelli represents private equity funds, hedge funds, venture capital funds, publicly traded companies, investment banks, financial institutions, entrepreneurs, emerging-growth companies and privately held companies in a variety of industries, including financial services, real estate, insurance, apparel, biosciences, software, Internet, media, energy and communications. Mr. Altorelli has extensive experience in the private equity industry and has represented some the major players including Blackstone, KKR, AEA Investors, Madison Dearborn, FdG Partners, AXA Private Equity, Ivory Capital, Canaan Partners and Conning Capital Partners. He also has represented large financial institutions including State Street Bank, Capmark Financial Group and GE Capital. He has helped many entrepreneurs, early stage and middle market companies from cradle to liquidity exits, including Agencourt Biosciences and Agencourt Personal Genomics. John earned his JD from Cornell Law School in 1993, was a recipient of the American Jurisprudence Award and an Editor of the Harvard Journal of Law & Public Policy: The Tenth Annual National Federalist Society Symposium on Law and Public Policy. He earned a B.S., summa cum laude, in Business Finance and Economics from Southern Connecticut State University in 1991 and was a recipient of the Henry Barnard Distinguished Student Award

Phillip R. Chapman, Board Member

Philip R. Chapman serves as President of Venad Administrative Services Inc., a management services company. Since 1993, Mr. Chapman has been President of Adler & Company. He serves as General Partner in Euro-America II LP, a private venture capital fund, and a Managing Partner of Zenith Asset Management, a private hedge fund. He has been Chairman of Shells Seafood Restaurants Inc. since April 2002 and has been its Director since May 1997 and is Chairman of Stock Option and Compensation Committee and Member of Executive Committee. He has been a Director of Regeneration Technologies Inc. since it began operations in February 1998 and is a Member of Compensation and Audit Committees and various private companies. He holds a B.S. and an M.B.A. from Columbia University.

Stephen M. McLean, Board Member

Mr. McLean was a founding partner of Merrill Lynch Capital Partners, Inc. (and its successor funds, Stonington Partners and Arena Capital Partners), a leader in the development of the Leveraged Buyout Industry. Over the last 25 years, Mr. McLean has helped to raise and manage aggregate private equity funds of $2.8 billion invested in a variety of companies including Borg Warner Corporation, First USA, Ann Taylor, Jack Eckerd Drug, Pathmark Stores, Denny's Restaurants, Simmons Mattress, and Education Management Corporation. Mr. McLean is also an active personal investor/board member of private companies in the healthcare industry focusing on Life Sciences, Medical Devices and Information Services. Mr. McLean was an investor in, and served as a director of, Agencourt Bioscience Corporation (reagents, sequencing services), Agencourt Personal Genomics (next-generation sequencing instrument), Packard Bioscience (analytical instruments), RS Medical Corporation (orthopedic devices), Obagi Medical (dermatological products), EduNeering Corporation (pharmaceutical/life science information services) and CentriHealth (Individualized Health Records). Mr. McLean is the Chairman of the International Biomedical Research Alliance, ("IBRA"). IBRA is a private sector foundation formed to support an advanced biomedical PhD program, the NIH/Oxford/ Cambridge Scholars Program, (the "Program"). The Program was established in 2000 by NIH to accelerate the training of American and British biomedical PhD's. It is the only academic program in the world to be an affiliate organization of the Rhodes scholarship. Mr. McLean holds an M.B.A. with Distinction from the Wharton School (1980) and a B.S. in Economics summa cum laude from the Wharton School, University of Pennsylvania (1979). He has been an occasional lecturer at Wharton for the Wharton Department of Business Ethics.

Richard Upton, Board Member

Richard Upton was most recently the founder and President of Upton Advisors, LLC, a boutique investment bank serving middle market and emerging healthcare companies throughout the United States. Mr. Upton has been advising early stage and growth stage companies since 1992 both as a senior healthcare investment banker for Salomon Brothers and later as an independent adviser. Mr. Upton has completed engagements representing aggregate transaction values in excess of $5 billion. Mr. Upton has served on the Board of Directors of six companies and helped start four companies. He currently serves on the Boards of Courtagen Life Sciences, Inc., Castlewood Surgical, and Carmell Therapeutics, and previously served on the Board of Home Diagnostics, Inc. (NASDAQ: HDIX – acquired by Nipro Corporation). Mr. Upton is a member of the Investment Committee of the New Hampshire Charitable Foundation, and is former Chairman of The Pine Hill Waldorf School. Mr. Upton is also a founding member of Northeast Angels, an early stage angel investing group based in southern New Hampshire. Mr. Upton received his MBA degree from The Darden School at the University of Virginia and a dual BA degree in Economics and English from Amherst College.